MX2011008131A - Lineas celulares que expresan cftr y los métodos para utilizarlas. - Google Patents

Lineas celulares que expresan cftr y los métodos para utilizarlas.

Info

Publication number
MX2011008131A
MX2011008131A MX2011008131A MX2011008131A MX2011008131A MX 2011008131 A MX2011008131 A MX 2011008131A MX 2011008131 A MX2011008131 A MX 2011008131A MX 2011008131 A MX2011008131 A MX 2011008131A MX 2011008131 A MX2011008131 A MX 2011008131A
Authority
MX
Mexico
Prior art keywords
cftr
cell
cells
intron
suppression
Prior art date
Application number
MX2011008131A
Other languages
English (en)
Spanish (es)
Inventor
Kambiz Shekdar
Dennis J Sawchuk
Jessica Langer
Srinivasan P Venkatachalan
Original Assignee
Chromocell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromocell Corp filed Critical Chromocell Corp
Publication of MX2011008131A publication Critical patent/MX2011008131A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y306/00Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03049Channel-conductance-controlling ATPase (3.6.3.49)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/38Pediatrics
    • G01N2800/382Cystic fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2011008131A 2009-02-02 2010-02-01 Lineas celulares que expresan cftr y los métodos para utilizarlas. MX2011008131A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14931209P 2009-02-02 2009-02-02
PCT/US2010/022778 WO2010088630A2 (en) 2009-02-02 2010-02-01 Cell lines expressing cftr and methods of using them

Publications (1)

Publication Number Publication Date
MX2011008131A true MX2011008131A (es) 2012-01-20

Family

ID=42396394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008131A MX2011008131A (es) 2009-02-02 2010-02-01 Lineas celulares que expresan cftr y los métodos para utilizarlas.

Country Status (6)

Country Link
US (2) US20120058918A1 (enExample)
EP (1) EP2393930A4 (enExample)
JP (1) JP2012516686A (enExample)
CA (1) CA2751215A1 (enExample)
MX (1) MX2011008131A (enExample)
WO (1) WO2010088630A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2245046B1 (en) * 2008-01-22 2019-09-04 Chromocell Corporation Novel cell lines expressing nav and methods using them
CA2713885A1 (en) * 2008-02-01 2009-08-20 Chromocell Corporation Novel cell lines and methods
WO2011014740A2 (en) 2009-07-31 2011-02-03 Chromocell Corporation Methods and composition for identifying and validating modulators of cell fate
WO2012162468A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Thiazol derivatives as pro -matrix metalloproteinase inhibitors
US20130014288A1 (en) * 2011-06-06 2013-01-10 Carnegie Mellon University Novel reporter-tagged recombinant membrane proteins with transmembrane linkers
FR2999191B1 (fr) * 2012-12-12 2016-02-05 Lesaffre & Cie Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
WO2017196843A1 (en) * 2016-05-09 2017-11-16 Proteostasis Therapeutics, Inc. Methods of identifying cftr modulators
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
WO2020056418A1 (en) 2018-09-14 2020-03-19 Neuroenhancement Lab, LLC System and method of improving sleep
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
CN111910008B (zh) * 2020-08-21 2022-05-31 云南农业大学 一种鸡生长发育相关的分子标记及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164782A1 (en) * 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
WO2001003722A1 (en) * 1999-07-09 2001-01-18 Mayo Foundation For Medical Education And Research Cftr polypeptides, fragments thereof and methods of use to overcome biosynthetic misprocessing
WO2004020596A2 (en) * 2002-08-30 2004-03-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Polypeptides for increasing mutant cftr channel activity
AU2005251745A1 (en) * 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
WO2006101740A2 (en) * 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof
CA2602793C (en) * 2005-04-13 2016-11-22 Astrazeneca Ab A host cell comprising a vector for production of proteins requiring gamma-carboxylation
MX2008014437A (es) * 2006-05-19 2008-11-27 Scripps Research Inst Tratamiento de desplegamiento de proteinas.
WO2008121199A2 (en) * 2007-03-28 2008-10-09 University Of Iowa Research Foundation Transgenic animal models of disease

Also Published As

Publication number Publication date
EP2393930A4 (en) 2012-08-15
CA2751215A1 (en) 2010-08-05
EP2393930A2 (en) 2011-12-14
US20120058918A1 (en) 2012-03-08
WO2010088630A3 (en) 2010-11-25
US20150315554A1 (en) 2015-11-05
JP2012516686A (ja) 2012-07-26
WO2010088630A2 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
MX2011008131A (es) Lineas celulares que expresan cftr y los métodos para utilizarlas.
Boeckers et al. C‐terminal synaptic targeting elements for postsynaptic density proteins ProSAP1/Shank2 and ProSAP2/Shank3
Quamme Molecular identification of ancient and modern mammalian magnesium transporters
Carneiro et al. The multiple LIM domain-containing adaptor protein Hic-5 synaptically colocalizes and interacts with the dopamine transporter
Ma et al. Diverse trafficking patterns due to multiple traffic motifs in G protein-activated inwardly rectifying potassium channels from brain and heart
ES2640817T3 (es) Líneas celulares que expresan Nav y métodos para su utilización
Piters et al. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function
CN103525751B (zh) 细胞系以及制备和使用其的方法
US20100105625A1 (en) Product and Methods for Diagnosis and Therapy for Cardiac and Skeletal Muscle Disorders
Tan et al. Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation
Park et al. Fine-tuning GPCR-mediated neuromodulation by biasing signaling through different G protein subunits
Stefanski et al. How T118M peripheral myelin protein 22 predisposes humans to Charcot–Marie–Tooth disease
Boileau et al. The short splice variant of the γ2 subunit acts as an external modulator of GABAA receptor function
Du et al. Functional characterization of novel NPRL3 mutations identified in three families with focal epilepsy
Edelheit et al. Identification of the roles of conserved charged residues in the extracellular domain of an epithelial sodium channel (ENaC) subunit by alanine mutagenesis
KR20070092767A (ko) 시노비올린 활성 조절 작용의 검출 방법
Larasati et al. Novel Mutation at Cys225 in GNAO1‐Associated Developmental and Epileptic Encephalopathies: Clinical, Molecular, and Pharmacological Profiling of Case Studies
EP3940384A1 (en) Method for screening compound for treating or preventing polyq-related neurodegenerative diseases
Dubreuil Molecular and genetic dissection of the membrane skeleton in Drosophila
Gu et al. The middle lipin (M-Lip) domain is a new dimeric protein fold that binds membranes
Dahimene et al. The interplay between splicing of exons 18a and 47 differentially affects membrane targeting and function of human CaV2. 2
Deb et al. DE NOVO VARIANTS IN THE POLY (RC)-BINDING PROTEIN GENE PCBP1 CAUSE A NEURODEVELOPMENTAL DISORDER
WO2002103057A1 (en) Methods for identifying modulators of nf-kb activity
Yan et al. Long-read sequencing-based atlas of tissue-specific expression of Drp1 transcript variants
Zhang et al. Novel Compound Heterozygous Pathogenic Mutations of SLC5A5 Novel Compound Heterozygous Pathogenic Mutations of SLC5A5 in a Chinese Patient With Congenital Hypothyroidism Cao-Xu Zhang¹†, Jun-Xiu Zhang2†, Liu Yang¹, Chang-Run Zhang¹

Legal Events

Date Code Title Description
FA Abandonment or withdrawal